BioMarin Pharmaceutical reported 53.62 in PE Price to Earnings for its fiscal quarter ending in September of 2026.





Pe Change Date
Acadia Pharmaceuticals 9.52 1.81 Sep/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
Alnylam Pharmaceuticals 13.17 62.47 Sep/2026
Amgen 18.6 0.53 Sep/2026
Bayer 4.61 0.47 Sep/2026
Biogen 29.15 5.92 Sep/2026
BioMarin Pharmaceutical 53.62 32.55 Sep/2026
Gilead Sciences 17.68 4.18 Sep/2026
Incyte 54.54 40.08 Sep/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 83.17 61.07 Sep/2026
PTC Therapeutics 8.76 0 Jun/2026
Puma Biotechnology 13.93 44.88 Jun/2024
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Roche Holding 16.48 0.39 Jun/2026
Sanofi 21.74 11.35 Sep/2026
Sarepta Therapeutics 32.09 22.66 Sep/2026
United Therapeutics 19.41 0.26 Sep/2026
Vertex Pharmaceuticals 29.35 1.3 Sep/2026